Potential Use of the Cholesterol Transfer Inhibitor U18666a As an Antiviral Drug for Research on Various Viral Infections

Potential Use of the Cholesterol Transfer Inhibitor U18666a As an Antiviral Drug for Research on Various Viral Infections Publisher Pubmed

Assefi M¹ ; Bijan Rostami R² ; Ebrahimi M³ ; Altafi M⁴ ; Tehrany PM⁵ ; Zaidan HK⁶ ; Talib Alnaqeeb BZ⁷ ; Hadi M⁸ ; Yasamineh S⁹ ; Gholizadeh O¹⁰

Show Affiliations

1. University of North Carolina at Greensboro, United States
2. School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
3. Shahid Babai Faculty of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran
4. Department of Microbiology, Faculty of Biological Science and Technology, Shiraz Pardis Branch, Islamic Azad University, Shiraz, Iran
5. Faculty of Medicine, National University of Malaysia, Bani, Malaysia
6. Department of Medical Laboratories Techniques, Al-Mustaqbal University College, Hillah, Babylon, Iraq
7. Anesthesia Technology Department, Al-Turath University College, Al Mansour, Baghdad, Iraq
8. Department of Basic Sciences, Tehran Central Branch, Islamic Azad University, Tehran, Iran
9. Department of Medical Biotechnology, Tabriz University of Medical Sciences, Tabriz, Iran
10. Department of Bacteriology and Virology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

Source: Microbial Pathogenesis Published:2023

Abstract

Cholesterol plays critical functions in arranging the biophysical attributes of proteins and lipids in the plasma membrane. For various viruses, an association with cholesterol for virus entrance and/or morphogenesis has been demonstrated. Therefore, the lipid metabolic pathways and the combination of membranes could be targeted to selectively suppress the virus replication steps as a basis for antiviral treatment. U18666A is a cationic amphiphilic drug (CAD) that affects intracellular transport and cholesterol production. A robust tool for investigating lysosomal cholesterol transfer and Ebola virus infection is an androstenolone derived termed U18666A that suppresses three enzymes in the cholesterol biosynthesis mechanism. In addition, U18666A inhibited low-density lipoprotein (LDL)-induced downregulation of LDL receptor and triggered lysosomal aggregation of cholesterol. According to reports, U18666A inhibits the reproduction of baculoviruses, filoviruses, hepatitis, coronaviruses, pseudorabies, HIV, influenza, and flaviviruses, as well as chikungunya and flaviviruses. U18666A-treated viral infections may act as a novel in vitro model system to elucidate the cholesterol mechanism of several viral infections. In this article, we discuss the mechanism and function of U18666A as a potent tool for studying cholesterol mechanisms in various viral infections. © 2023 Elsevier Ltd

Related Docs

View other Related Docs

1. An Overview of the Role of Niemann-Pick C1 (Npc1) in Viral Infections and Inhibition of Viral Infections Through Npc1 Inhibitor, Cell Communication and Signaling (2023)

2. Potential Use of Proprotein Convertase Subtilisin/Kexin Type 9 (Pcsk9) Inhibition and Prevention Method in Viral Infection, Microbial Cell Factories (2024)

3. The Potential Use of Bacteria and Bacterial Derivatives As Drug Delivery Systems for Viral Infection, Virology Journal (2023)

4. Spotlight on the Impact of Viral Infections on Hematopoietic Stem Cells (Hscs) With a Focus on Covid-19 Effects, Cell Communication and Signaling (2023)

5. Recent Advances on High-Efficiency of Micrornas in Different Types of Lung Cancer: A Comprehensive Review, Cancer Cell International (2023)

6. The Role of Bismuth Nanoparticles in the Inhibition of Bacterial Infection, World Journal of Microbiology and Biotechnology (2023)

7. Rare Predicted Loss-Of-Function Variants of Type I Ifn Immunity Genes Are Associated With Life-Threatening Covid-19, Genome Medicine (2023)

8. Spotlight on Therapeutic Efficiency of Green Synthesis Metals and Their Oxide Nanoparticles in Periodontitis, Journal of Nanobiotechnology (2024)

Experts (# of related papers)

Hamid Reza Mirzaei (1)

SeyedMohamad Hosseini Hooshiyar (1)

Style	Citing Format
MLA	Assefi M, et al.. "Potential Use of the Cholesterol Transfer Inhibitor U18666a As an Antiviral Drug for Research on Various Viral Infections." Microbial Pathogenesis, vol. 179, no. , 2023, pp. -.
APA	Assefi M, Bijan Rostami R, Ebrahimi M, Altafi M, Tehrany PM, Zaidan HK, Talib Alnaqeeb BZ, Hadi M, Yasamineh S, Gholizadeh O (2023). Potential Use of the Cholesterol Transfer Inhibitor U18666a As an Antiviral Drug for Research on Various Viral Infections. Microbial Pathogenesis, 179(), -.
Chicago	Assefi M, Bijan Rostami R, Ebrahimi M, Altafi M, Tehrany PM, Zaidan HK, Talib Alnaqeeb BZ, Hadi M, Yasamineh S, Gholizadeh O. "Potential Use of the Cholesterol Transfer Inhibitor U18666a As an Antiviral Drug for Research on Various Viral Infections." Microbial Pathogenesis 179, no. (2023): -.
Harvard	Assefi M et al. (2023) 'Potential Use of the Cholesterol Transfer Inhibitor U18666a As an Antiviral Drug for Research on Various Viral Infections', Microbial Pathogenesis, 179(), pp. -.
Vancouver	Assefi M, Bijan Rostami R, Ebrahimi M, Altafi M, Tehrany PM, Zaidan HK, et al.. Potential Use of the Cholesterol Transfer Inhibitor U18666a As an Antiviral Drug for Research on Various Viral Infections. Microbial Pathogenesis. 2023;179():-.
BibTex	@article{ author = {Assefi M and Bijan Rostami R and Ebrahimi M and Altafi M and Tehrany PM and Zaidan HK and Talib Alnaqeeb BZ and Hadi M and Yasamineh S and Gholizadeh O}, title = {Potential Use of the Cholesterol Transfer Inhibitor U18666a As an Antiviral Drug for Research on Various Viral Infections}, journal = {Microbial Pathogenesis}, volume = {179}, number = {}, pages = {-}, year = {2023} }
RIS	TY - JOUR AU - Assefi M AU - Bijan Rostami R AU - Ebrahimi M AU - Altafi M AU - Tehrany PM AU - Zaidan HK AU - Talib Alnaqeeb BZ AU - Hadi M AU - Yasamineh S AU - Gholizadeh O TI - Potential Use of the Cholesterol Transfer Inhibitor U18666a As an Antiviral Drug for Research on Various Viral Infections JO - Microbial Pathogenesis VL - 179 IS - SP - EP - PY - 2023 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract